Supplementary Table.

Table 1: Studies considered for the analysis:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **N pts per study** | **N pts randomized to DOX 75** | **N pts considered in this analysis** | **References****(First author, year, title, Journal)** |
| **EORTC 62901**R. Ph II/III | 334 | 112 | 101 | O.S. NIELSEN et al. (1998), High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Br.J. Cancer 78 (12): 1634-1639 |
| **EORTC 62941**R. Ph II | 86 | 42 | 38 | J. VERWEIJ et al. (2000), Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 18: 2081-2086 |
| **EORTC 62962**R. Ph II | 95 | 45 | 41 | I. JUDSON et al. (2001), Randomised phase II trial of pegylated liposomal doxorubicin (Doxil®/Caelyx®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC soft tissue and bone sarcoma group. Eur J Cancer 37: 870-877 |
| **EORTC 62971**R. Ph III | 326 | 110 | 99 | P. LORIGAN et al. (2007), Phase III Trial of two investigational schedules of Ifosfamide compared with standard-dose Doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25 (21): 3144-3150 |
| **EORTC 62012**R. Ph III | 445 | 228 | 203 | I JUDSON et al. (2014), Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. S1470-2045(14)70063-4 |
| **EORTC 62061**R. Ph II | 118 | 39 | 37 | H. GELDERBLOM H et al. (2014), Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. Eur J Cancer. 50(2):388-96 |
| **EORTC 62091**R. Ph II/III | 133 | 43 | 38 | B. BUI-NGUYEN et al (2015). A phase IIB multicenter study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer. 51 (10): 1312-20. |

R=randomised; DOX=doxorubicin.